Arcellx (ACLX) said Wednesday that a phase 2 study of anitocabtagene autoleucel showed that patients with relapsed or refractory multiple myeloma demonstrated an overall response rate of 97%.
The results also showed a complete response/stringent complete response rate of 68% and a very good partial response or higher rate of 85%, based on International Myeloma Working Group criteria as investigator-assessed, the company said.
Arcellx said no delayed or non-immune effector cell-associated neurotoxicity syndrome neurotoxicities have been observed to date with the therapy.
The company said it plans a commercial launch for the therapy in 2026.
Shares were up 6.2% in recent trading.
Price: 61.86, Change: +3.61, Percent Change: +6.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.